This phenomenon is in accordance with a prior research finding that PI3Kα inhibition with CYH33 triggers antitumor immunity in breast cancer by activating CD8 + T cells18, suggesting a potential synergistic effect of combining CYH33 with immune checkpoint inhibitors. The gene discussed is CD8A; the disease is breast carcinoma.